Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAWID M SARWARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1649698630
CMS profile
4226112
Location
ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,044.07

247 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,679.62 241
Long term medical supply or device loan $183.03 2
Education $181.42 4

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $651.02 23
Takeda Pharmaceuticals U.S.A., Inc. $372.28 13
GlaxoSmithKline, LLC. $340.84 16
Eisai Inc. $300.41 11
Daiichi Sankyo Inc. $296.76 10
Merck Sharp & Dohme LLC $291.04 11
Janssen Biotech, Inc. $269.00 12
AstraZeneca Pharmaceuticals LP $226.73 10
PFIZER INC. $218.71 14
Incyte Corporation $210.80 9
ABBVIE INC. $210.04 10
E.R. Squibb & Sons, L.L.C. $181.97 12
Bayer Healthcare Pharmaceuticals Inc. $171.65 8
Genentech USA, Inc. $126.21 5
GENZYME CORPORATION $124.87 4
ARRAY BIOPHARMA INC $119.83 5
Celgene Corporation $116.75 5
Gilead Sciences, Inc. $116.56 4
PUMA BIOTECHNOLOGY, INC. $107.35 4
Boehringer Ingelheim Pharmaceuticals, Inc. $103.27 4
SOBI, INC $89.07 4
Stemline Therapeutics Inc. $85.59 3
Exelixis Inc. $76.34 2
Amgen Inc. $65.44 2
Aveo Pharmaceuticals, Inc. $64.29 2
Octapharma USA, Inc. $62.50 2
BeiGene USA, Inc. $61.12 2
Deciphera Pharmaceuticals Inc. $60.95 3
Alexion Pharmaceuticals, Inc. $54.65 2
Iovance Biotherapeutics, Inc. $53.29 2
Pharmacosmos Therapeutics Inc. $52.26 2
RECORDATI_RARE_DISEASES_INC. $49.36 2
Boston Scientific Corporation $48.80 1
Lilly USA, LLC $45.68 2
EMD Serono, Inc. $39.52 1
Sumitomo Pharma America, Inc. $38.53 2
Dendreon Pharmaceuticals LLC $32.32 1
TerSera Therapeutics LLC $32.21 1
Genmab U.S., Inc. $31.32 1
Kite Pharma, Inc. $30.65 1
Novocure Inc. $30.20 1
Astellas Pharma US Inc $27.69 1
Immunocore Limited $25.84 1
Karyopharm Therapeutics Inc. $25.64 1
Rigel Pharmaceuticals, Inc. $25.48 1
KYOWA KIRIN, INC. $25.00 1
Agios Pharmaceuticals, Inc. $24.96 1
Ipsen Biopharmaceuticals, Inc $24.62 1
Geron Corporation $22.65 1
Coherus Oncology, Inc. $21.90 1
TAIHO ONCOLOGY, INC. $20.62 1
Blueprint Medicines Corporation $19.46 1
PharmaEssentia USA Corporation $19.34 1
Telix Pharmaceuticals $18.78 1
Verity Pharmaceuticals Inc. $17.23 1
Caris MPI, Inc. $16.76 1
SERVIER PHARMACEUTICALS LLC $16.42 1
Janssen Pharmaceuticals, Inc $15.99 1
Azurity Pharmaceuticals, Inc. $15.51 1

Page 5 of 5; records 201–247 of 247 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAWID M SARWARI

NPI 1649698630 · CMS profile ID 4226112

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–247 of 247 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649698630?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–247 of 247 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649698630?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–247 of 247 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649698630?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–247 of 247 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1649698630?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

247 matching records · $6,044.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 247 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–247 of 247.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $15.9502/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174544160 CMS
Lilly USA, LLC $30.3902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186837542 CMS
GlaxoSmithKline, LLC. $18.5402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191045387 CMS
Novartis Pharmaceuticals Corporation $83.3302/21/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200424106 CMS
Astellas Pharma US Inc $27.6902/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238757020 CMS
BeiGene USA, Inc. $30.5502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202881072 CMS
AstraZeneca Pharmaceuticals LP $24.6902/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207142438 CMS
ARRAY BIOPHARMA INC $33.7502/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231573879 CMS
Eisai Inc. $24.4702/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244502134 CMS
GlaxoSmithKline, LLC. $20.8002/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190809380 CMS
Alexion Pharmaceuticals, Inc. $30.4302/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202962630 CMS
Gilead Sciences, Inc. $28.9102/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234445245 CMS
SOBI, INC $25.7702/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240265758 CMS
ARRAY BIOPHARMA INC $17.2302/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231557298 CMS
E.R. Squibb & Sons, L.L.C. $22.7102/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184671269 CMS
Daiichi Sankyo Inc. $28.9002/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197044119 CMS
GlaxoSmithKline, LLC. $17.5802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190642493 CMS
Lilly USA, LLC $15.2902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186825630 CMS
PFIZER INC. $29.0802/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231359055 CMS
Novartis Pharmaceuticals Corporation $31.8102/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200424112 CMS
Daiichi Sankyo Inc. $27.4302/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197045239 CMS
Janssen Biotech, Inc. $20.8502/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174544304 CMS
PFIZER INC. $11.9002/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230012382 CMS
PFIZER INC. $9.3801/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231652738 CMS
E.R. Squibb & Sons, L.L.C. $23.5501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184671239 CMS
Janssen Biotech, Inc. $22.9201/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174544470 CMS
Novartis Pharmaceuticals Corporation $28.6401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200424114 CMS
SOBI, INC $22.9801/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240265763 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.9901/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223033188 CMS
Eisai Inc. $29.3601/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244502130 CMS
Exelixis Inc. $35.4501/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218800349 CMS
Novartis Pharmaceuticals Corporation $99.7001/23/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200424104 CMS
PFIZER INC. $12.7001/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231275526 CMS
Novartis Pharmaceuticals Corporation $22.8701/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200424118 CMS
ABBVIE INC. $30.6301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204070272 CMS
Janssen Biotech, Inc. $20.4001/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174544920 CMS
Celgene Corporation $18.2001/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184671263 CMS
Eisai Inc. $25.4001/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244502132 CMS
Kite Pharma, Inc. $30.6501/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212082833 CMS
Deciphera Pharmaceuticals Inc. $17.5101/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235961169 CMS
Alexion Pharmaceuticals, Inc. $24.2201/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202966314 CMS
Genentech USA, Inc. $31.5901/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211558696 CMS
Celgene Corporation $19.8101/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184671255 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.8101/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223911910 CMS
Merck Sharp & Dohme LLC $24.9501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238235889 CMS
PFIZER INC. $4.9301/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231119199 CMS
GlaxoSmithKline, LLC. $22.8601/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191038557 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $245.89 2
PY2020 $3,704.99 64
PY2021 $7,521.17 161
PY2022 $4,395.48 214
PY2023 $5,386.30 248
PY2024 $6,680.72 252
PY2025 $6,044.07 247

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,254.58 38
PY2024 Principal investigator $21,904.46 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $40.89 12/19/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612688
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731074
Principal investigator 1 Hoffmann-La Roche Limited $6,812.10 12/01/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612692
Principal investigator 1 Hoffmann-La Roche Limited $300.00 11/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612684
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731072
Principal investigator 1 Hoffmann-La Roche Limited $35.90 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612664
Principal investigator 1 Hoffmann-La Roche Limited $39.92 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612672
Principal investigator 1 Hoffmann-La Roche Limited $36.58 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612652
Principal investigator 1 Hoffmann-La Roche Limited $39.50 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612676
Principal investigator 1 Hoffmann-La Roche Limited $472.50 10/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612680
Principal investigator 1 Hoffmann-La Roche Limited $212.50 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612644
Principal investigator 1 Hoffmann-La Roche Limited $7,352.10 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612660
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731070
Principal investigator 1 Hoffmann-La Roche Limited $2,112.75 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612640
Principal investigator 1 Hoffmann-La Roche Limited $11,194.20 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612648
Principal investigator 1 Hoffmann-La Roche Limited $250.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612655
Principal investigator 1 Hoffmann-La Roche Limited $108.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612669
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612602
Principal investigator 1 Hoffmann-La Roche Limited $445.50 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612635
Principal investigator 1 Hoffmann-La Roche Limited $45.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612617
Principal investigator 1 Hoffmann-La Roche Limited $37.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612625
Principal investigator 1 Hoffmann-La Roche Limited $30.85 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612631
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612606
Principal investigator 1 Hoffmann-La Roche Limited $41.88 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612628
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731050
Principal investigator 1 Hoffmann-La Roche Limited $12.94 08/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612621
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731048
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731054
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731056
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731058
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731060
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731062
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731064
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731066
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731068
Principal investigator 1 Hoffmann-La Roche Limited $29.82 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612609
Principal investigator 1 Hoffmann-La Roche Limited $25.87 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612613
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731052